Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study-Reference-Cited by-同舟云学术

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

Published:2015-05 Issue:2 Volume:88 Page:215-222
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Moro-Sibilot Denis,Smit Egbert,de Castro Carpeño Javier,Lesniewski-Kmak Krzysztof,Aerts Joachim,Villatoro Rosa,Kraaij Kees,Nacerddine Karim,Dyachkova Yulia,Smith Karen T.,Taipale Kaisa,Girvan Allicia C.,Visseren-Grul Carla,Schnabel Philipp A.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years;Cufer;Eur J Cancer,2012

2. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review;Goffin;J Thorac Oncol,2010

3. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Peters;Ann Oncol,2012

4. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010;Felip;Ann Oncol,2011

5. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry;Clinical and Translational Oncology;2024-06-11

2. Prognostic Value of Inflammation and Nutrition-Based Scores in Non-Small Cell Lung Cancer;Medical Principles and Practice;2023-12-13

3. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review;Frontiers in Oncology;2023-09-04

4. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis;Cancer Medicine;2023-04-19

5. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib;Pulmonology;2022-12